Patients eligible for transplant

How do you think transplant eligible high-risk multiple myeloma should be managed after induction?

L: English

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Ben Derman, University of Chicago Medical Center, Chicago, US answers the question: How do you think transplant eligible high-risk multiple myeloma should be managed after induction?

Ben Derman discusses the treatment options for transplant eligible patients who have completed induction therapy. He talks about the results from multiple trials such as the STAMINA trial, that has transplantation as a treatment arm. Ben Derman also discusses the results from the FORTE trial, EMORY trial, the Myeloma XI study, and the IFM-2009 and explains the patient outcomes in each study.